Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 1/10

vs
industry
vs
history
Cash to Debt 0.51
NSPR's Cash to Debt is ranked higher than
57% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.27 vs. NSPR: 0.51 )
NSPR' s 10-Year Cash to Debt Range
Min: 0.34   Max: No Debt
Current: 0.51

Equity to Asset -0.65
NSPR's Equity to Asset is ranked lower than
56% of the 453 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. NSPR: -0.65 )
NSPR' s 10-Year Equity to Asset Range
Min: -0.65   Max: 0.78
Current: -0.65

-0.65
0.78
F-Score: 2
Z-Score: -20.61
M-Score: -8.06
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -661.03
NSPR's Operating margin (%) is ranked lower than
55% of the 458 Companies
in the Global Medical Devices industry.

( Industry Median: 5.49 vs. NSPR: -661.03 )
NSPR' s 10-Year Operating margin (%) Range
Min: -309.32   Max: -228.66
Current: -661.03

-309.32
-228.66
Net-margin (%) -692.86
NSPR's Net-margin (%) is ranked lower than
55% of the 458 Companies
in the Global Medical Devices industry.

( Industry Median: 3.95 vs. NSPR: -692.86 )
NSPR' s 10-Year Net-margin (%) Range
Min: -600.41   Max: -244.25
Current: -692.86

-600.41
-244.25
ROE (%) -514.97
NSPR's ROE (%) is ranked lower than
57% of the 443 Companies
in the Global Medical Devices industry.

( Industry Median: 5.07 vs. NSPR: -514.97 )
NSPR' s 10-Year ROE (%) Range
Min: -434.39   Max: -256.02
Current: -514.97

-434.39
-256.02
ROA (%) -148.25
NSPR's ROA (%) is ranked lower than
56% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.61 vs. NSPR: -148.25 )
NSPR' s 10-Year ROA (%) Range
Min: -436.36   Max: -187.49
Current: -148.25

-436.36
-187.49
ROC (Joel Greenblatt) (%) -3539.78
NSPR's ROC (Joel Greenblatt) (%) is ranked lower than
56% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 8.37 vs. NSPR: -3539.78 )
NSPR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1517.86   Max: -1255.56
Current: -3539.78

-1517.86
-1255.56
» NSPR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with NSPR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 16.00
NSPR's P/S is ranked higher than
54% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 3.40 vs. NSPR: 16.00 )
NSPR' s 10-Year P/S Range
Min: 7.96   Max: 54
Current: 16

7.96
54
EV-to-EBIT -2.37
NSPR's EV-to-EBIT is ranked higher than
59% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 73.45 vs. NSPR: -2.37 )
NSPR' s 10-Year EV-to-EBIT Range
Min: -49.3   Max: -1.8
Current: -2.37

-49.3
-1.8
Current Ratio 0.81
NSPR's Current Ratio is ranked lower than
56% of the 474 Companies
in the Global Medical Devices industry.

( Industry Median: 2.72 vs. NSPR: 0.81 )
NSPR' s 10-Year Current Ratio Range
Min: 0.13   Max: 4.68
Current: 0.81

0.13
4.68
Quick Ratio 0.63
NSPR's Quick Ratio is ranked lower than
54% of the 474 Companies
in the Global Medical Devices industry.

( Industry Median: 1.95 vs. NSPR: 0.63 )
NSPR' s 10-Year Quick Ratio Range
Min: 0.13   Max: 4.28
Current: 0.63

0.13
4.28

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.92
NSPR's Price/Median PS Value is ranked higher than
79% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 1.21 vs. NSPR: 0.92 )
NSPR' s 10-Year Price/Median PS Value Range
Min: 0.52   Max: 2.86
Current: 0.92

0.52
2.86
Earnings Yield (Greenblatt) -42.20
NSPR's Earnings Yield (Greenblatt) is ranked lower than
53% of the 464 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. NSPR: -42.20 )
NSPR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -42.2

Business Description

Industry: Medical Devices » Medical Devices
Compare: » details
InspireMD, Inc. was organized in the State of Delaware on February 29, 2008 as Saguaro Resources, Inc. to engage in the acquisition, exploration and development of natural resource properties. On March 28, 2011, it effectuated a 1-for-3 forward stock split and changed its name from 'Saguaro Resources, Inc.' to 'InspireMD, Inc.' It is an innovative medical device company focusing on the development and commercialization of its proprietary stent platform technology, MGuard. MGuard provides embolic protection in stenting procedures by placing a micron mesh sleeve over a stent. The Company's initial products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). According to the TYPHOON STEMI trial and the SOS SVG Trial of patients with acute myocardial infarction and saphenous vein graft coronary interventions, 7.5% to 44% experience major adverse cardiac events, including cardiac death, heart attack, and restenting of the artery. When performing stenting procedures in patients with acute coronary symptoms, interventional cardiologists face a difficult dilemma in choosing between bare-metal stents, which have a high rate of restenosis (formation of new blockages), and drug-eluting (drug-coated) stents, which have a high rate of late thrombosis (formation of clots months or years after implantation), require administration of anti-platelet drugs for at least one year post procedure, are more costly than bare-metal stents and have additional side effects. It intends to use its MGuard technology in a broad range of coronary related situations in which complex lesions are required and make it an industry standard for treatment of acute coronary syndromes. It also intends to apply its technology to develop additional products used for other vascular procedures, specifically carotid (the arteries that supply blood to the brain) and peripheral (other arteries) procedures. The Company markets its products through distributers in international markets, mainly in Europe and Latin America.
» More Articles for NSPR

Headlines

Articles On GuruFocus.com
InspireMD Reports 4 Significant Insider Buys Apr 19 2013 

More From Other Websites
INSPIREMD, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 12 2014
INSPIREMD, INC. Files SEC form 10-Q, Quarterly Report Nov 12 2014
InspireMD Reports Financial Results for the Third Quarter ended September 30, 2014 Nov 12 2014
INSPIREMD, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Nov 10 2014
InspireMD Completes $8.1 Million Registered Direct Offering Nov 07 2014
InspireMD to Report Financial Results for the Third Quarter Ended September 30, 2014 on Wednesday,... Nov 06 2014
InspireMD to Report Financial Results for the Third Quarter Ended September 30, 2014 on Wednesday,... Nov 05 2014
INSPIREMD, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of... Nov 05 2014
InspireMD Announces Registered Direct Offering for Approximately $8 Million Nov 04 2014
InspireMD Announces Registered Direct Offering for Approximately $8 Million Nov 04 2014
InspireMD Investigational Device Exemption (IDE) Amendment Approved by the FDA Oct 29 2014
INSPIREMD, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Oct 29 2014
InspireMD Investigational Device Exemption (IDE) amendment approved by the FDA Oct 29 2014
InspireMD, Inc. (NSPR) Surges: Stock Moves 12.4% Higher Oct 21 2014
INSPIREMD, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events,... Oct 14 2014
InspireMD Resumes MGuard Prime Sales and Prioritizes DES and Carotid - New Product Programs Oct 14 2014
INSPIREMD, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Oct 01 2014
InspireMD Announces Initial Commercial Sales of the CGuard™ EPS Oct 01 2014
INSPIREMD, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 19 2014
InspireMD to Host Conference Call and Webinar and to Discuss Recently Released Results of CGuard™... Sep 18 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK